Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORPHEUS C gastric and gastroesophageal junction cancer umbrella study
CTR20212909Phase 2Active
- Sponsor
- Roche
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tiragolumab, atezolizumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Roche. Started Mar 2022; status: active.
02
Drugs
tiragolumabatezolizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20212909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212909.